Orphazyme cuts guidance following FDA setback
![Photo: Spar Nord/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13067806.ece/ALTERNATES/schema-16_9/doc7g9y5rdatugywr2zb42.jpg)
It's a hard blow for Orphazyme that the US Food and Drug Administration (FDA) has rejected the biotech firm's main candidate arimoclomol for the treatment of the metabolic disease Niemann-Pick type C (NPC).
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.